Clinical Trials Logo

Clinical Trial Summary

Prospective (analysis of retrospective data), multi-center, observational, single-arm study. This structure was selected as the "worst case" due to the fact that it represents real life usage of invasive FFR measurement is performed mostly in "gray zone" cases, which are that their severity cannot be determined intuitively and based on the physician eyeball. By using real-world historical data of invasive FFR, the analysis of the obtained data can ensure that the study results are expected to include invasive FFR results that are in the grey zone, when invasive FFR is used in real life and represent the real expected use of the product. Furthermore, the analysis of the data obtained in the studies with these similar devices measuring FFR obtained from angiograms was actually performed in a retrospective manner. That is, although the angiographic images and pressure wire recordings were obtained in real-time, due to the need to mark the vessel in real-time and obtain specific projections during the procedure without which the FFR cannot be calculated, the primary endpoint (sensitivity and specificity) and accuracy were determined in all studies by a post-hoc review by a similar independent QCA core laboratory. The invasive FFR data, as well as the software generated FFR data were reviewed post-hoc by a core laboratory or even at the company.

Clinical Trial Description

The proposed study is designed to compare MedHub AutocathFFR measurements obtained from angiograms for the non-invasive determination of the presence of hemodynamically significant coronary lesions. The software device will run on angiograms generated during cardiac catheterization and results will be compared to invasive FFR measurements. The study is a prospective (analysis of retrospective data), multi-center, observational, single-arm, study. A total of 308 cases will be enrolled in the study. The study population who represent the target population for this procedure consists of subjects with stable angina, unstable angina or NSTEM1 who underwent a clinically indicated invasive coronary angiography and for whom invasive FFR have been measured in vessels with coronary lesions. For each lesion of interest, a minimum of two 2D angiographic projections, will be obtained. Patients of both genders, all ethnicities, >18 years of age will be recruited to the study. Study cases will be sourced from numerous hospitals in the United States and Israel. Investigators will screen cases based on the inclusion/exclusion criteria described below. General patient demographics, medical history, concomitant medications, C-arm angiography system used, FFR pressure wire used, etc., will be obtained for each study case. Subjects with known or suspected coronary artery disease who were scheduled for clinically indicated invasive coronary angiography (ICA) and on whom invasive FFR has been measured in vessels with coronary lesions will comprise the patient population. Coronary angiography will have been performed in a routine fashion in patients with suspected coronary artery disease. When clinically indicated, invasive FFR will have been measured in vessels with coronary lesions of varying severity using a coronary pressure wire and hyperemic stimulus. The patient's angiographic images will be sent to an independent Quantitative Coronary Arteriography (QCA) Core Laboratory, where they will be processed using the MedHub AutocathFFR device, by independent potential users of the device (i.e., interventional cardiologists). The users will use the diagnostic angiograms and upload them to the AutocathFFR device, to generate the AutocathFFR value. The independent users will be blinded to the software device-generated FFR results and to the invasive FFR measurements. Blinding will be employed in the study because the primary endpoint, i.e., the scored FFR measurements per vessel are subject to bias by device users. Observations in patients with more than 1 study vessel will be presumed independent. The AutocathFFR will not be used for diagnostic or clinical decisions. A detailed standard operating procedure (SOP) for AutoCathFFR computation will be provided to the QCA Core Laboratory. The AutocathFFR device automatically suggests and marks locations of suspicious narrowing and computes an FFR value for each detected area. The clinician can also select and mark manually locations with suspected narrowing for computing of FFR value. The clinical performance of AutocathFFR device depends only on the uploaded angiograms, on which the AutocathFFR results are presented alongside the viewed blood vessel. There is no need for user interaction with the system during the diagnostic angiography procedure. For example, there is no need to take specific orthogonal projection nor to designate or mark the blood vessels or segments. When the desired coronary artery is viewed on the Cath Lab monitor, the AutocathFFR measurement is automatically shown alongside the viewed vessel, if an area of narrowing is identified in the vessel. Therefore, the use of the AutocathFFR device is seamless with the angiographic imaging procedure and does not require any additional intervention by the cardiologist. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT04861519
Study type Observational
Source Medhub Ltd.
Status Not yet recruiting
Start date May 1, 2021
Completion date June 30, 2021

See also
  Status Clinical Trial Phase
Completed NCT04097912 - Study to Gather Information to What Extent Patients Follow the Treatment Regimen of Low-dose Aspirin for Primary and Secondary Prevention of Diseases of the Heart and Blood Vessels
Not yet recruiting NCT03610529 - CardioSenseSystem Compared Study Regarding Efficacy and Safety in the Monitoring of ECG N/A
Withdrawn NCT03906812 - A Randomized Trial of Telemetry Compared With Unmonitored Floor Admissions in ED Patients With Low-Risk Chest Pain N/A
Completed NCT01826552 - Comparison of the Angiographic Result of the Orsiro Hybrid Stent With Resolute Integrity Stent Phase 4
Completed NCT01709669 - The Impact of Gratitude on Biology and Behavior in Persons With Heart Disease N/A
Completed NCT01688648 - Comparison Between Lidocaine, Dexmedetomidine, and Their Combined Infusion in Subjects Undergoing Coronary Artery Bypass Graft N/A
Completed NCT01171404 - Study Evaluating How Patients With Acute Coronary Syndrome Are Managed During 2 Years After Discharge N/A
Completed NCT01020383 - Comparative Study of ALX-0081 Versus GPIIb/IIIa Inhibitor in High Risk Percutaneous Coronary Intervention (PCI) Patients Phase 2
Completed NCT01167582 - Myocardial Ischemia and Transfusion Pilot Phase 3
Terminated NCT00355992 - The Ischemia Modified Albumin In Diagnosing Ischemic New Events N/A
Completed NCT00449826 - Risk Stratification of Non ST Elevation ACS With Computed Tomographic Angiography (REACT) N/A
Completed NCT00263263 - RRISC Study: Reduction of Restenosis In Saphenous Vein Grafts With Cypher Sirolimus-Eluting Stent. Phase 2
Completed NCT03103620 - Safety and Effectiveness Evaluation of COBRA PzF Coronary Stent System: A Post Marketing Observational Registry
Recruiting NCT04648306 - Restore EF Observational Study
Not yet recruiting NCT03266289 - Evaluation of Short Term Outcome of Different Bifurcation Stenting Techniques at Assuit University Cath. Lab N/A
Not yet recruiting NCT04403048 - Drug Coated Balloon for Side Branch Treatment vs. Conventional Approach in True Bifurcation Coronary Disease: PRO-DAVID N/A
Recruiting NCT02748603 - Appropriateness of Coronary Angioplasty in PAtients With isCHEmic Heart Disease N/A
Completed NCT01774838 - Vasoactive and Anti-inflammatory Effects of Prasugrel in Acute Coronary Syndrome Phase 3
Completed NCT01974492 - Comparison of Saphenous Vein Graft Harvested From Upper Versus Lower Leg in Coronary Artery Bypass Grafting N/A
Completed NCT01990924 - Low Rate Fluoroscopy to Reduce Radiation Dose During Coronary Angiography and Intervention N/A